drug

Fenretinide

MeSH D017313
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Beersheva Mental Health Center
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
NCT00534898Phase 3Withdrawn

KOLs & investigators

2
Prof. Vladimir Lerner, MD, PhDKOL score 5
Chanoch Miodownik, MDKOL score 0

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Beersheva Mental Health Center
company
trial
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
PHASE3
trial
indication
Schizophrenia
indication
Cognition
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Prof. Vladimir Lerner, MD, PhD
KOL score 5
person
Chanoch Miodownik, MD
KOL score 0
person